OBJECTIVE: This study describes the presence of mutations in BRCA1 and BRCA2 genes in a group of Mexican women and the clinical evolution of early onset breast cancer (EOBC). MATERIAL AND METHODS: A prospective hospital-based study was performed in a sample of 22 women with EOBC (7 in clinical stage IIA, 8 in IIB, and 7 in IIIA). The patients attended a tertiary care hospital in northeastern Mexico in 1997 and were followed up over a 5-year period. Molecular analysis included: 1) a mutation screening by heteroduplex analysis (HA) of BRCA1 and BRCA2 genes and 2) a sequence analysis. RESULTS: Of 22 patients, 14 (63.6%) showed a variant band detected by heteroduplex analysis of the BRCA1 and BRCA2 genes: 8 polymorphisms, 4 mutations of uncertain significance, and 2 novel truncated protein mutations, one in BRCAI (exon 11, 3587delT) and the other in the BRCA2 gene (exon 11, 2664InsA). CONCLUSIONS: These findings support future studies to determine the significance and impact of the genetic factor in this Mexican women population.
OBJECTIVE: This study describes the presence of mutations in BRCA1 and BRCA2 genes in a group of Mexican women and the clinical evolution of early onset breast cancer (EOBC). MATERIAL AND METHODS: A prospective hospital-based study was performed in a sample of 22 women with EOBC (7 in clinical stage IIA, 8 in IIB, and 7 in IIIA). The patients attended a tertiary care hospital in northeastern Mexico in 1997 and were followed up over a 5-year period. Molecular analysis included: 1) a mutation screening by heteroduplex analysis (HA) of BRCA1 and BRCA2 genes and 2) a sequence analysis. RESULTS: Of 22 patients, 14 (63.6%) showed a variant band detected by heteroduplex analysis of the BRCA1 and BRCA2 genes: 8 polymorphisms, 4 mutations of uncertain significance, and 2 novel truncated protein mutations, one in BRCAI (exon 11, 3587delT) and the other in the BRCA2 gene (exon 11, 2664InsA). CONCLUSIONS: These findings support future studies to determine the significance and impact of the genetic factor in this Mexican women population.
Authors: Filipa Lynce; Kristi D Graves; Lina Jandorf; Charite Ricker; Eida Castro; Laura Moreno; Bianca Augusto; Laura Fejerman; Susan T Vadaparampil Journal: Cancer Control Date: 2016-10 Impact factor: 3.302
Authors: Cynthia Villarreal-Garza; Rosa María Alvarez-Gómez; Carlos Pérez-Plasencia; Luis A Herrera; Josef Herzog; Danielle Castillo; Alejandro Mohar; Clementina Castro; Lenny N Gallardo; Dolores Gallardo; Miguel Santibáñez; Kathleen R Blazer; Jeffrey N Weitzel Journal: Cancer Date: 2014-09-18 Impact factor: 6.860
Authors: Gabriela Torres-Mejía; Robert Royer; Marcia Llacuachaqui; Mohammad R Akbari; Anna R Giuliano; Louis Martínez-Matsushita; Angélica Angeles-Llerenas; Carolina Ortega-Olvera; Elad Ziv; Eduardo Lazcano-Ponce; Catherine M Phelan; Steven A Narod Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-11-04 Impact factor: 4.254
Authors: C Villarreal-Garza; J N Weitzel; M Llacuachaqui; E Sifuentes; M C Magallanes-Hoyos; L Gallardo; R M Alvarez-Gómez; J Herzog; D Castillo; R Royer; Mohammad Akbari; F Lara-Medina; L A Herrera; A Mohar; S A Narod Journal: Breast Cancer Res Treat Date: 2015-02-26 Impact factor: 4.872
Authors: Marcia Cruz-Correa; Julyann Pérez-Mayoral; Julie Dutil; Miguel Echenique; Rafael Mosquera; Keila Rivera-Román; Sharee Umpierre; Segundo Rodriguez-Quilichini; Maria Gonzalez-Pons; Myrta I Olivera; Sherly Pardo Journal: Hered Cancer Clin Pract Date: 2017-01-21 Impact factor: 2.857
Authors: J C Fernández-Lopez; S Romero-Córdoba; R Rebollar-Vega; L A Alfaro-Ruiz; S Jiménez-Morales; F Beltrán-Anaya; R Arellano-Llamas; A Cedro-Tanda; M Rios-Romero; M Ramirez-Florencio; V Bautista-Piña; C Dominguez-Reyes; F Villegas-Carlos; A Tenorio-Torres; A Hidalgo-Miranda Journal: Hum Genomics Date: 2019-01-10 Impact factor: 4.639
Authors: Julie Dutil; Volha A Golubeva; Alba L Pacheco-Torres; Hector J Diaz-Zabala; Jaime L Matta; Alvaro N Monteiro Journal: Breast Cancer Res Treat Date: 2015-11-12 Impact factor: 4.872